BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37798659)

  • 21. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 22. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
    Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
    Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The identification of Lynch syndrome in Congolese colorectal cancer patients.
    Poaty H; Aba Gandzion C; Soubeyran I; Gassaye D; Peko JF; Nkoua Bon JB; Gombé Mbalawa C
    Bull Cancer; 2017 Oct; 104(10):831-839. PubMed ID: 28988047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancer.
    Karpel HC; Smith M; Brodsky A; Pothuri B
    Gynecol Oncol; 2023 Aug; 175():20-24. PubMed ID: 37290248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
    Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
    Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart TL; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Cancer; 2021 Sep; 127(17):3082-3091. PubMed ID: 33983630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 29. Lynch Syndrome in Thai Endometrial Cancer Patients.
    Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
    Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome.
    Cerrato C; Pandolfo SD; Autorino R; Panunzio A; Tafuri A; Porcaro AB; Veccia A; De Marco V; Cerruto MA; Antonelli A; Derweesh IH; Maresma MCM
    World J Urol; 2023 Jul; 41(7):1741-1749. PubMed ID: 36964236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.
    Shia J; Tang LH; Vakiani E; Guillem JG; Stadler ZK; Soslow RA; Katabi N; Weiser MR; Paty PB; Temple LK; Nash GM; Wong WD; Offit K; Klimstra DS
    Am J Surg Pathol; 2009 Nov; 33(11):1639-45. PubMed ID: 19701074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for Lynch syndrome identification in selected and unselected gynecological cancers.
    Carnevali I; Sahnane N; Chiaravalli AM; Di Lauro E; Facco C; Facchi S; Casarin J; Ghezzi F; Sessa F; Tibiletti MG
    Eur J Cancer Prev; 2022 Jul; 31(4):369-376. PubMed ID: 34519692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Genetic analysis of 45 patients with suspected Lynch syndrome using next-generation sequencing].
    Yao ZG; Cheng XK; Lin CH; Li J; Lyu BB; Li JM; Jing HY; Qin YJ; Sun XC
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):843-849. PubMed ID: 34407589
    [No Abstract]   [Full Text] [Related]  

  • 35. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers.
    Evans DG; Lalloo F; Ryan NA; Bowers N; Green K; Woodward ER; Clancy T; Bolton J; McVey RJ; Wallace AJ; Newton K; Hill J; McMahon R; Crosbie EJ
    J Med Genet; 2022 Apr; 59(4):328-334. PubMed ID: 33452216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Should we systematically screen for Lynch syndrome in patients with upper urinary tract carcinoma?].
    Olagui GS; Pignot G; Rouquette A; Vieillefond A; Amsellem-Ouazana D; de Longchamps NB; Radenen B; Zerbib M; Terris B
    Bull Cancer; 2014 Feb; 101(2):144-50. PubMed ID: 24556207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
    Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
    Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Lynch syndrome risk variants in the Romanian population.
    Iordache PD; Mates D; Gunnarsson B; Eggertsson HP; Sulem P; Benonisdottir S; Csiki IE; Rascu S; Radavoi D; Ursu R; Staicu C; Calota V; Voinoiu A; Jinga M; Rosoga G; Danau R; Sima SC; Badescu D; Suciu N; Radoi V; Mates IN; Dobra M; Nicolae C; Kristjansdottir S; Jonasson JG; Manolescu A; Arnadottir G; Jensson B; Jonasdottir A; Sigurdsson A; le Roux L; Johannsdottir H; Rafnar T; Halldorsson BV; Jinga V; Stefansson K
    J Cell Mol Med; 2018 Dec; 22(12):6068-6076. PubMed ID: 30324682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.